Top 15 Global Pharmaceutical Company Awards $1 Million in Study Extensions to eResearchTechnology for Cardiac Safety Monitoring
18 May 2004 - 12:12AM
PR Newswire (US)
Top 15 Global Pharmaceutical Company Awards $1 Million in Study
Extensions to eResearchTechnology for Cardiac Safety Monitoring and
Information Distribution Services Awards Include a Series of Late
Phase Studies for Multiple Indications for Two Key Clinical
Development Programs PHILADELPHIA, May 17 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has been awarded
study extensions totaling approximately $1 million in cardiac
safety monitoring and services from a top 15 global pharmaceutical
organization under a previously executed Franchise agreement for
two of its key drug candidates in later phase clinical trials. The
awards cover extensions to a series of Phase II and Phase III
studies that target several indications. eRT is already providing
comprehensive support for these studies, including provision of
digital 12-lead ECG equipment designed to facilitate collection of
cardiac safety data that is subsequently provided to eRT for
analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow-enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
"eRT is pleased to be in a position to rapidly respond to the
increased needs of two of this sponsors' key clinical development
programs," said Scott Grisanti, senior vice president of business
development and chief marketing officer at eRT. "Trial extensions
are becoming more common as the new drug development industry
implements adaptive clinical trial strategies that are designed to
enable an agile response to evolving regulatory requirements and to
act on initial trial feedback while studies are still in process.
eRT's Global Customer Care capabilities, including digital ECG
equipment marshalling and distribution, along with comprehensive
site education curricula and support, are proving critical to
effectively executing significant trial extensions as exemplified
by these awards." Based in Philadelphia, PA, eResearchTechnology,
Inc. (http://www.ert.com/) is a provider of technology and services
to the pharmaceutical, biotechnology and medical device industries
on a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
These studies may be canceled by the sponsor at its sole
discretion. As a result, actual results may differ materially from
any financial outlooks stated herein. Further information on
potential factors that could affect the company's financial results
can be found in the company's Reports on Forms 10-K and 10-Q filed
with the Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles